Grifols vs Veradermics

Grifols (GRFS), health care, and Veradermics (MANE), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Grifols is worth $5.9B on the stock market and Veradermics $5.3B: Grifols is valued at 11% more. Over the past year Grifols's share price has moved +1.51% and Veradermics's +239%.

Key facts

Grifols market value
$5.9B
Veradermics market value
$5.3B
Grifols P/E
10.4
Grifols revenue
$8.3BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Grifols vs Veradermics: every measure side by side
Measure Grifols Veradermics
SectorHealth CareHealth Care
Country Spain United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$5.9Bhigher$5.3Blower
Revenue$8.3B—
Earnings$446Mhigher-$70Mlower
Employees25,000higher37lower
Total assets$21.9Bhigher$152.6Mlower
Valuation
P/E10.4—
P/S0.7—
P/B—6.7
Dividend yield—0.00%
Profitability
Operating margin16.5%—
Balance sheet
Net assets$5.8Bhigher-$121Mlower
Total liabilities$13.4Bhigher$9.2Mlower
Total debt——
Cash on hand$915.3Mhigher$21.8Mlower
Price change
Today-1.15%higher-1.88%lower
1 year+1.51%lower+239%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Grifols only (1)

Veradermics only (2)

Percentages are each holding's share of that investor's reported portfolio. Who owns GRFS · Who owns MANE

Further comparisons

Learn

Questions and answers

Which is bigger, Grifols or Veradermics?

By market value, Grifols is the larger: $5.9B against $5.3B for Veradermics.

Which superinvestors own both Grifols and Veradermics?

None of the tracked superinvestors holds both in their latest 13F filing. 1 holds Grifols and 2 hold Veradermics.

Cite this page

Funkfolio, “Grifols vs Veradermics”, data as of 17 November 2026. https://funkfolio.com/compare/grfs-vs-mane

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.